Lobbying registration dated 2026-03-17
Registrant: Robbie Levac
Client: Johnson & Johnson (Canada) Inc.
Targeted institutions:
Justice Canada (JC)
Finance Canada (FIN)
Canadian Institutes of Health Research (CIHR)
Treasury Board Of Canada Secretariat (TBS)
Public Services and Procurement Canada (PSPC)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Global Affairs Canada (GAC)
Public Health Agency of Canada (PHAC)
Immigration, Refugees and Citizenship Canada (IRCC)
Privy Council Office (PCO)
Senate of Canada
Health Canada (HC)
Acts: Food and Drugs Act
Government funding received:
Lobbying activity details:
Canada’s engagement in international trade agreements in particular Comprehensive and Economic Trade Agreement (CETA) and North American Free Trade Canada-United States-Mexico Agreement (NAFTACUSMA) and any other agreements as it relates to intellectual property considerations and other aspects which affect the local business environment for J&J companies.
Modernizations of the Food and Drugs Act, with respect to inspection, reporting and confidential business information.
Local manufacturing of healthcare products – Regarding the development of policies and programs (including funding programs) to support the expansion of existing manufacturing facilities or the establishment of additional manufacturing capacity in Canada.
Communication to officials on labelling and product monographs.
Development of Health Emergency Readiness Canada agency, and its role in promoting development of life sciences sector in Canada
Health Canada and the Patented Medicine Prices Review Board (PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
Proposed national pharmacare. Specifically, government’s intention to introduce a national pharmacare program.
Engagement on government’s Innovation Agenda Biomanufacturing and Life Sciences Strategy as it relates to Health and Bio Sciences sector. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in Canada, including the use and development of medical devices, digital health and robotics.
Health Canada’s multi-year Regulatory Modernization initiative to modernize the Food and Drugs Act and Regulations, specifically with respect to approval, regulation and life cycle management of therapeutic products, including Agile Regulations.
COVID-19: Regarding the development of policies and programs to address the COVID-19 pandemic and support the recovery of the Canadian economy, including as it relates to tackling health equity across marginalized communities in Canada and surgical backlogs.
Discuss Canada’s talent attraction strategy as part of the expansion of the nation’s industrial and research capacity.
Canada’s partnerships on global health and global community impact with Johnson & Johnson relating to maternal and child health, First Nations, mental health and other areas.
Food and Drugs Act: Delays in product approvals and changes to existing products.
Treasury Board initiative to address international regulatory cooperation as well as their work on the Canada US, and Canada EU Regulatory Cooperation Councils
Zero plastic waste by 2030 – Regarding potential legislative proposal regulating harmful single-use plastic items and implementing implementation of plastic waste management programs and impact on medical technologies.
Chemical Management Plan as related to the regulation of chemical substances, particularly as affecting ingredients used in therapeutic products.
Canadian Drug Agency: Specifically, the creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.